GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Cash Conversion Cycle

Shanghai HeartCare Medical Technology (HKSE:06609) Cash Conversion Cycle : 805.45 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Shanghai HeartCare Medical Technology's Days Sales Outstanding for the six months ended in Dec. 2023 was 101.18.
Shanghai HeartCare Medical Technology's Days Inventory for the six months ended in Dec. 2023 was 720.66.
Shanghai HeartCare Medical Technology's Days Payable for the six months ended in Dec. 2023 was 16.39.
Therefore, Shanghai HeartCare Medical Technology's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 805.45.


Shanghai HeartCare Medical Technology Cash Conversion Cycle Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Cash Conversion Cycle Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
- 201.56 264.26 540.55 807.40

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only 184.48 379.34 583.10 948.16 805.45

Competitive Comparison of Shanghai HeartCare Medical Technology's Cash Conversion Cycle

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's Cash Conversion Cycle falls into.



Shanghai HeartCare Medical Technology Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Shanghai HeartCare Medical Technology's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=80.74+747.64-20.98
=807.40

Shanghai HeartCare Medical Technology's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=101.18+720.66-16.39
=805.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology  (HKSE:06609) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Shanghai HeartCare Medical Technology Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines